NCT01210248

Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Assaf-Harofeh Medical Center · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to check correlation between CYP2C19 genotype level of clopidogrel metabolite in plasma and platelet inhibition status.

Detailed description

THE FIRST PHASE OF THE RESEARCH WILL INVOLVE PATIENTS RECRUITMENT AND INFORMED CONSENT FOR GENETIC TESTING.THE MAJORITY OF PATIENTS WILL BE RECRUITED FROM EMERGENCY DEPARTMENT. EVERY PATIENT WILL BE ASKED ABOUT HIS AND HIS PARENT'S ETHNICITY (ASHKENASI OR SEPHARDY JEW) AND ADDITIONAL DRUGS HE TAKES. IF PATIENT AGREES TO PARTICIPATE IN THE STUDY , HIS BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS: 1. GENETIC (FOR CYP450 2C19) 2. PLATELET MAPPING TEST ( BY THROMBOELASTOGRAPH ASSAY) 3. CLOPIDOGREL INACTIVE METABOLITE DETERMINATION BY CHROMATOGRAPHIC METHOD

Conditions

• PRIMARY FOCUS:PATIENT THAT TAKE CLOPIDOGREL

Interventions

Type	Name	Description
OTHER	BLOOD COLLECTION	BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS

Timeline

• Start date: 2010-09-01
• Primary completion: 2012-01-01
• First posted: 2010-09-28
• Last updated: 2010-09-28

Locations

1 site across 1 country: Israel